This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the benefits and harms of EGFR inhibitors in the treatment of metastatic colorectal cancer when given alone, in combination with chemotherapy, or with other biological agents.
Specific primary objective
To determine the effect of EGFR inhibitors on progression free survival.
To determine the effect of EGFR inhibitors on:
Tumour response rates
Quality of life
Studies will be categorised by drug class (monoclonal antibodies v TKIs v other), the use of EGFR inhibitors alone or in combination with chemotherapy and/or other biological agents such as anti-angiogenic therapy and by their position in the metastatic colorectal cancer treatment paradigm - first line, second line or 3rd line.